Does a 250 mg Intramammary Syringe Remain Homogeneous After 18 Months at 25°C/60% RH?

Formulations containing cefalonium dihydrate veterinary-grade API for dry cow intramammary administration are commonly produced as sterile oil-based suspensions, with each prefilled syringe delivering 250 mg cefalonium activity in a 5 g dose. Because the β-lactam ring remains sensitive to hydrolytic opening, the vehicle is normally an anhydrous mineral oil or a medium-chain triglyceride thickened with aluminium stearate or hydrophobic fumed silica. Isotonicity is not the primary requirement in the teat cistern, but particle retention in the mammary gland is controlled through a narrow particle-size window. Laser diffraction analysis per ISO 13320:2020 is used to verify that Dv90 remains below 25 µm and Dv10 remains above 1 µm. A Dv10 below 1 µm increases the probability of excessive systemic absorption, while a Dv90 above 25 µm increases the risk of physical clogging in the streak canal. Viscosity is maintained within 1,200–3,500 mPa·s at 20°C using a cone-plate rotational rheometer according to ISO 3219. The suspension is thixotropic so that it flows under manual syringe pressure but recovers a gel-like structure after placement in the mammary quarter. Batch production begins with screening of the API through a 600 µm mesh to remove hard agglomerates, followed by high-shear dispersion into the oil phase under vacuum below 100 mbar to avoid entrained air. The dispersed phase is then passed through a rotor-stator homogenizer at a tip speed of 15–20 m/s until the target particle-size distribution is reached. Terminal sterilization by dry heat or moist heat is generally incompatible with cephalosporins because the β-lactam ring degrades rapidly above 60°C in the presence of moisture; therefore, aseptic assembly of presterilized components is more common. Filling into multilayer polyethylene intramammary syringes is performed in Grade A cleanroom conditions under Grade B background, and gravimetric fill-weight checks are conducted at 15 min intervals. Release testing includes sterility per Ph. Eur. 2.6.1, bacterial endotoxins per Ph. Eur. 2.6.14, extractable volume per Ph. Eur. 2.9.17, and assay by high-performance liquid chromatography. The finished product is labelled with milk-withholding and meat-withholding periods specified in the registered summary of product characteristics, and those periods are not identical across all markets.

At the outer boundary of cefalonium formulation work, aqueous injectable solutions expose a pH-dependent solubility profile that narrows the practical concentration window. Cefalonium dihydrate is a zwitterionic cephalosporin, and its water solubility is lowest near the isoelectric point. Manufacturing-scale operations use pH adjustment with dilute hydrochloric acid or sodium hydroxide to move the solution away from the isoelectric point, but pH values below 4.0 accelerate β-lactam degradation and pH values above 8.0 promote base-catalyzed hydrolysis. Concentrations above 100 mg/mL are generally not achievable without co-solvents or complexing agents, and published solubility data for this specific molecular form remain limited. When a sterile injectable suspension is produced instead of a solution, particle-size control becomes more stringent because intramuscular administration requires a Dv90 below 10 µm to reduce injection-site irritation. Wet milling under nitrogen in a bead mill charged with 0.3 mm yttrium-stabilized zirconia beads can reduce the API to the target size within 45–90 min, depending on chamber volume and agitator speed. The suspending vehicle may contain sodium carboxymethylcellulose at 0.3–0.8% w/v and polysorbate 80 at 0.05–0.1% w/v, but the exact composition must be confirmed by forced degradation studies because polysorbate can contain peroxides that oxidize the cephalosporin sulfur. Sterilization of the finished injectable is often performed by aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane because moist-heat autoclaving at 121°C for 15 min degrades the β-lactam ring. Filled vials are tested for particulate matter by light obscuration per USP <788>, sterility per USP <71>, and bacterial endotoxins per USP <85>. Production-scale failure modes documented for cephalosporin injectables include filter fouling at low temperature, pH drift during nitrogen sparging, and assay loss after terminal electron-beam irradiation above 25 kGy; therefore, irradiation dose mapping is required if terminal treatment is used.

When Direct Compression Replaces Wet Granulation, Tablet Hardness Must Not Exceed 8 kp

Oral solid dosage forms containing cefalonium are manufactured in dry environments because the hydrated β-lactam ring hydrolyzes under aqueous granulation conditions. Direct compression is therefore preferred over high-shear wet granulation, but cefalonium dihydrate has poor compactability, so a filler-binder system of microcrystalline cellulose at 40–60% w/w and lactose monohydrate at 25–40% w/w is used. Disintegrant crospovidone at 2–4% w/w and lubricant sodium stearyl fumarate at 0.5–1.0% w/w are common alternatives when magnesium stearate is withheld because its hydrophobic film can delay dissolution of a poorly water-soluble cephalosporin, although the exact delay depends on blending time and shear input. Process conditions on a rotary tablet press include compression force adjusted to produce hardness of 6–8 kp, with friability below 1.0% after 100 revolutions per USP <1216>. Hardness above 10 kp can reduce dissolution below the required Q value at 30 min in 0.1 M hydrochloric acid, and hardness below 4 kp can increase tablet capping during pan coating. Capsules are filled with a powder blend that is often compacted into slugs and milled, or filled as a direct blend, with capsule fill weight adjusted according to assay. The process is conducted at relative humidity below 40% RH because moisture uptake above 2.0% w/w accelerates the appearance of hydrolytic impurities. Stability protocols follow ICH Q1A(R2) for zones I–IV, and dissolution method development uses apparatus II at 50 rpm with 900 mL of a suitable medium. Production-scale failures include punch filming caused by inadequate lubrication, moisture-induced crosslinking of crospovidone at high humidity, and assay drift in long compression runs when the API segregates in the hopper due to particle-size differences between API and excipients.

When cefalonium is converted into a dry syrup or reconstitutable granule, the primary stability challenge is moisture ingress through the closure system. Granulation is usually performed by top-spray fluid-bed processing at an inlet air temperature of 55–65°C and an outlet air temperature of 30–38°C, with a binder solution sprayed at 8–12 g/min per kilogram of substrate. The binder is often a low-viscosity hydroxypropylcellulose or povidone solution at 2–5% w/w, but povidone may contain residual peroxides that require control. The granulated material is dried to loss on drying below 2.0% w/w, sized through a 1.0 mm sieve, and then blended with buffer salts such as sodium citrate and citric acid to achieve a reconstituted pH of 5.0–5.5. Reconstitution tests are conducted with purified water at 25°C, and the suspension must pass through a 0.5 mm sieve without visible particles. Chemical stability of reconstituted cefalonium oral suspensions is limited; the product is typically labelled for 7 days at 2–8°C unless confirmed otherwise by stability studies. The dry powder is packed under nitrogen in aluminium foil laminates with a moisture vapor transmission rate below 0.5 g/m²/24 h at 40°C/90% RH according to ASTM F1249. Fill weight and moisture content are monitored every 30 min during filling, and the headspace oxygen is maintained below 3.0%. The product is tested for dose uniformity by USP <905> and for bacterial endotoxins by Ph. Eur. 2.6.14 if the oral powder is used in neonatal animals. Field failure data indicate that clumping inside sachets is the most frequent defect when the heat-seal temperature exceeds 180°C, because heat transfer to the powder bed raises local moisture activity.

Premix Carryover in Multi-Species Feed Mills and the Role of Sequential Flushing

Medicated premix operations handling cefalonium must be segregated from non-antibiotic production lines, and the process is subject to veterinary prescription controls rather than growth-promotion use. In the European Union, medicated feed is regulated under Regulation (EU) 2019/4; carryover limits and feeding-stuff hygiene are managed through validated cleaning and production sequencing. Dry mixing usually uses a horizontal ribbon blender with working volume 70–80% of nominal capacity, a ribbon tip speed of 2–4 m/s, and total mixing time 15–20 min after the API has been pre-blended with a carrier such as lactose monohydrate or wheat semolina at a 1:9 ratio. Homogeneity is assessed by sampling at 10 locations across the blender according to ISO 6497 or an equivalent sampling standard, and only blends with coefficient of variation below 5.0% for cefalonium assay are released for dilution. The premix is generally diluted at 0.5–5.0 kg per tonne of final feed, depending on the prescribed dose, but the exact inclusion rate is determined by the registered summary of product characteristics. Sequential flushing is used after cefalonium batches; the first flush batch is usually at least 10% of mixer capacity and is analyzed before the line returns to non-antibiotic feed. Cross-contamination acceptance limits are not harmonized globally; Regulation (EU) 2019/4 requires that carryover of antibiotics be below a maximum level established by risk assessment or the applicable carryover limit for the substance when authorized. The finished premix is packed in multiwall paper sacks with an inner polyethylene liner, and the moisture content is controlled below 5.0% w/w because cefalonium hydrolysis accelerates in damp carriers. Production-scale failure modes include electrostatic adhesion of micronized API to stainless-steel walls, incomplete discharging from dead zones in the ribbon blender, and assay stratification when particle-size ratios exceed 1:10 between API and carrier.

Unlike dry syrup reconstitution, aqueous oral solutions containing cefalonium are produced only in small batch volumes because the β-lactam ring is hydrolyzed in water at a rate that increases with temperature and pH deviation from 5.0–6.0. The solution is prepared in a jacketed stainless-steel vessel at 20–25°C, with stirring at 200–400 rpm for a maximum of 4 h before the final pH check. Buffering with citrate or phosphate is required; phosphate buffers above 0.05 M can reduce cephalosporin solubility through salt effects. Sweeteners such as sorbitol or sodium saccharin are added before the API to avoid localized osmotic stress, and the solution is sparged with nitrogen to keep dissolved oxygen below 1.0 mg/L. The product is filled into amber polyethylene terephthalate bottles with child-resistant closures and stored at 2–8°C; an in-use study is required to define the maximum hold time after first opening. The finished solution is tested for pH, assay, related substances, and microbial quality per Ph. Eur. 5.1.3 if it is not sterile. If the solution is intended for parenteral or ophthalmic use, it must be sterile-filtered through a 0.22 µm membrane and aseptically filled. Published production-scale data for cefalonium oral solutions in food-producing species remain limited, and local prescribing restrictions must be verified because cephalosporin use in some jurisdictions is limited to non-food animals or prohibited for mass medication.